Product News

Share this article:

GlaxoSmithKline submitted follow-up data and information to the FDA for Cervarix, the company's cervical cancer drug. Cervarix would become the second HPV vaccine on the market in the US, competing with Merck's Gardasil. GSK submitted data from its phase 3 trials, HPV-008. FDA had already reviewed interim data from the same trial, and requested more information. GSK expects FDA's review of Cervarix's biologics license application to take six months.

 

Novartis announced FDA's approval of Afinitor, a kidney cancer drug. Afinitor is indicated for patients with advanced renal cell carcinoma, after failure of treatment with sunitinib or sorafenib.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.